Search Browse Earnings

Kura Oncology, Inc.

Nasdaq:KURA

Pharmaceutical Preparations·SAN DIEGO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Kura Oncology, Inc. — SlamSEC

Revenue

$0

-100.0% YoY

FY 2025

Adj. EBITDA

-$165.0M

FY 2025

Net Income

-$152.6M

FY 2025

EPS (Diluted)

-$2.08

FY 2025

Stock Price

$8.96

+5.7%

2026-03-06

52W Range

$5.41 – $12.49

P/E Ratio

-4.3x

Market Cap

$791.0M

Cash

$224.5M

FY 2025

Total Debt

$6.9M

FY 2025

Net Cash

$217.5M

FY 2025

Enterprise Value

$573.4M

Debt / EBITDA

1.3x

FY 2025

EV / EBITDA

-3.5x

Employees

—